genedrive plc

Equities

EHP

GB00B1VKB244

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 11:35:19 2024-04-26 am EDT			5-day change	1st Jan Change
5.375 ^GBX	-4.44%		-8.51%	-33.85%

Apr. 24	Genedrive enters clinical trial deal in US for MT-RNR1 US approval	AN
Apr. 03	FTSE 100 up thanks to US economic data	AN

Genedrive draws down GBP600,000 on prepayment facility

January 02, 2024 at 05:58 am EST

Genedrive PLC - Manchester, England-based molecular diagnostics company - Draws down GBP600,000 on its GBP5 million equity prepayment facility. In March last year, Genedrive agreed the GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd. At the time it said that proceeds would be used towards the commercialisation of the antibiotic-induced hearing loss test, Genedrive MT-RNR1 ID Kit, and enhancing the Genedrive platform as well as providing additional working capital.

Current stock price: 8.20 pence

12-month change: down 33%

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GENEDRIVE PLC	5.375 GBX	-4.44%	-8.51%	9.58M
	RIVERFORT GLOBAL OPPORTUNITIES PLC	0.22 GBX	-.--%	-.--%	2.12M

Latest news about genedrive plc

Genedrive enters clinical trial deal in US for MT-RNR1 US approval	Apr. 24	AN
FTSE 100 up thanks to US economic data	Apr. 03	AN
Genedrive shares surge as UK's NICE backs test for ischaemic stroke	Apr. 03	AN
AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal	Apr. 03	AN
Genedrive's Test Receives Draft Recommendation from UK's NICE	Apr. 03	MT
EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate	Mar. 28	AN
Genedrive plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 28	CI
Genedrive down as plans equity raise despite GBP800,000 tax credit	Mar. 15	AN
Coro seals sale terms, Powerhouse makes good progress	Feb. 19	AN
Genedrive Seeks Funding for Testing Kit Amid Funding Call Launch of UK-backed Program	Feb. 19	MT
MoneySupermarket credits Insurance for growth in 2023	Feb. 19	AN
Genedrive draws down GBP600,000 on prepayment facility	Jan. 02	AN
Genedrive Secures Financing Under Equity Prepayment Facility	Jan. 02	MT
AIM WINNERS & LOSERS: Genedrive shares jump on orders	Dec. 20	AN
Genedrive shares surge as six countries receive first orders	Dec. 20	AN
Genedrive Jumps on Receipt of Initial Orders for MT-RNR1 Products	Dec. 20	MT
Genedrive plc Announces Initial Overseas Orders of Mt-RNR1 Id Kit	Dec. 20	CI
600 Group disposal and funding talks continue	Dec. 04	AN
Genedrive plc Announces the Genedrive MT-RNR1 Id Kit Is Now in Routine Use in the Trevor Mann Baby Unit	Dec. 04	CI
Genedrive shares fall as annual loss widens but focused on investing	Nov. 30	AN
Earnings Flash (GDR.L) GENEDRIVE Reports FY23 Revenue GBP55,000	Nov. 30	MT
Earnings Flash (GDR.L) GENEDRIVE Posts FY23 Loss GBX-5.50	Nov. 30	MT
Genedrive plc Reports Earnings Results for the Full Year Ended June 30, 2023	Nov. 30	CI
EARNINGS AND TRADING: Southern Energy loss swing; Craven House widens	Nov. 29	AN
Genedrive to receive GBP1.2 million grant for test kit	23-09-28	AN

Chart genedrive plc

Duration

Period

More charts

Company Profile

genedrive plc is a United Kingdom-based patient molecular diagnostics company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company offers products, including Genedrive MT-RNR1 ID Kit and Genedrive COV19-ID Kit. Genedrive MT-RNR1 ID Kit is a rapid genetic test in an emergency neonatal care setting. It has developed tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of hepatitis c virus (HCV), infection prior to drug administration, pathogen detection of biological military threats, and a point-of-care for COVID-19 detection system for us in areas such as healthcare, workplace screening, travel requirements, or confirmation of antigen tests.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-11-18 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
GENEDRIVE PLC	-33.85%	9.58M
SARTORIUS AG	-12.91%	19.08B
QUIDELORTHO CORPORATION	-46.21%	2.65B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+18.15%	1.87B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-3.12%	1.61B
BIOTAGE AB	+23.78%	1.21B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-10.69%	1.02B
CONTEC MEDICAL SYSTEMS CO.,LTD	-20.89%	905M
REVENIO GROUP OYJ	-7.14%	716M
VAREX IMAGING CORPORATION	-18.10%	682M

Medical Diagnostic & Testing Equipment